Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
CTLA-4, cytotoxic T lymphocyte associated antigen 4
ICI, immune checkpoint inhibitors
LAG-3, lymphocyte-activation gene 3
MSI, microsatellite instability
PD-L1, programmed death-ligand 1
TMB, tumor mutational burden
TME, tumor microenvironment
biomarkers
cardio-oncology
cardiotoxicity
immune checkpoint inhibitors
immune related adverse events
immunotherapy
irAE, immune-related adverse event
medical oncology
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
13
05
2022
accepted:
07
09
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that have significantly improved the prognosis of various cancers, both in (neo)adjuvant and metastatic settings. Unlike other conventional therapies, ICIs elicit antitumor effects by enhancing host immune systems to eliminate cancer cells. There are 3 approved ICI classes by the U.S. Food and Drug Administration: inhibitors targeting cytotoxic T lymphocyte associated antigen 4, programmed death 1/programmed death-ligand 1, and lymphocyte-activation gene 3, with many more in development. ICIs are commonly associated with distinct toxicities, known as immune-related adverse events, which can arise during treatment or less frequently be of late onset, usually relating to excessive activation of the immune system. Acute cardiovascular immune-related adverse events such as myocarditis are rare; however, data suggesting chronic cardiovascular sequelae are emerging. This review presents the current landscape of ICIs in oncology, with a focus on important aspects relevant to cardiology.
Identifiants
pubmed: 36636451
doi: 10.1016/j.jaccao.2022.09.004
pii: S2666-0873(22)00447-1
pmc: PMC9830229
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
579-597Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Dr Tan is supported by a postgraduate scholarship from the National Health and Medical Research Council of Australia, a PhD scholarship from the National Heart Foundation of Australia, and an Australian Government Research Training Program Scholarship. Dr Day is a recipient of the Royal Australasian College of Physicians Foundation 2022 Basser Research Entry Scholarship; and has received research support (clinical trials for the institution) from Beigene, Bristol-Myers Squibb, EpimAb, Harbour BioMed, Maxinovel, MSD, Olema Pharmaceuticals, Pfizer, PhamAbcine, and Roche. Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron; and served as a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Expert Rev Cardiovasc Ther. 2013 Jan;11(1):55-9
pubmed: 23259445
Blood. 2019 Oct 3;134(14):1144-1153
pubmed: 31409671
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
N Engl J Med. 2018 Sep 13;379(11):e18
pubmed: 30207917
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Oncologist. 2011;16(1):5-24
pubmed: 21212434
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2018 Jan;89:56-63
pubmed: 29227818
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Am J Clin Oncol. 2015 Feb;38(1):90-7
pubmed: 25616204
JAMA Oncol. 2018 Sep 1;4(9):e180077
pubmed: 29566106
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31988143
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Med J Aust. 2021 Apr;214(7):318-323
pubmed: 33296507
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405
pubmed: 35390769
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267
pubmed: 35082367
JAMA Oncol. 2021 May 1;7(5):744-748
pubmed: 33764387
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
J Am Heart Assoc. 2020 Jan 21;9(2):e013757
pubmed: 31960755
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
Eur J Cancer. 2017 Mar;73:1-8
pubmed: 28064139
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Nat Rev Drug Discov. 2019 Nov;18(12):899-900
pubmed: 31780841
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32532839
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
JAMA Oncol. 2019 Oct 01;5(10):1411-1420
pubmed: 31343665
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Nature. 1993 Nov 4;366(6450):76-9
pubmed: 7694153
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
J Clin Oncol. 2022 Oct 10;40(29):3467-3469
pubmed: 35709408
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326555
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33653801
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
JAMA Oncol. 2021 Oct 1;7(10):1573-1574
pubmed: 34383012
Cancers (Basel). 2021 Jan 10;13(2):
pubmed: 33435262
Front Immunol. 2021 Jun 29;12:669150
pubmed: 34267748
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
JACC CardioOncol. 2021 Mar;3(1):35-47
pubmed: 33842895
Lancet. 2021 Aug 28;398(10302):759-771
pubmed: 34454674
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
JAMA Oncol. 2020 Jun 1;6(6):865-871
pubmed: 32297899
Front Immunol. 2021 Sep 27;12:730320
pubmed: 34646270
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1304-1312
pubmed: 32522832
JAMA Oncol. 2020 Dec 1;6(12):1952-1956
pubmed: 33119034
Gastric Cancer. 2019 Jul;22(4):828-837
pubmed: 30911859
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
N Engl J Med. 2022 Feb 3;386(5):449-462
pubmed: 35108470
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546
pubmed: 31367835
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer Discov. 2019 Apr;9(4):510-525
pubmed: 30622105
Lancet Oncol. 2021 Jul;22(7):919-930
pubmed: 34051177
Nature. 2018 Oct;562(7725):20-21
pubmed: 30279600
J Clin Oncol. 2019 Dec 1;37(34):3291-3299
pubmed: 31609651
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
J Clin Oncol. 2019 Apr 10;37(11):867-875
pubmed: 30811280
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Ann Oncol. 2021 Oct;32(10):1276-1285
pubmed: 34293460
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2022 Mar 1;40(7):752-761
pubmed: 34990208
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
J Exp Med. 1995 Aug 1;182(2):459-65
pubmed: 7543139
Nat Commun. 2022 Jan 19;13(1):392
pubmed: 35046403
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Br Med J. 1957 Apr 13;1(5023):841-7
pubmed: 13413231
Clin Cancer Res. 2021 Nov 1;27(21):5993-6000
pubmed: 34376536
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
J Am Coll Cardiol. 2022 Feb 15;79(6):577-593
pubmed: 35144750
Lancet Oncol. 2021 Jun;22(6):848-857
pubmed: 34000246
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Cancer Immunol Immunother. 2005 Apr;54(4):307-14
pubmed: 15599732
N Engl J Med. 1998 Apr 30;338(18):1272-8
pubmed: 9562581
Front Pharmacol. 2017 Oct 18;8:730
pubmed: 29093678
J Clin Oncol. 2019 Oct 20;37(30):2730-2737
pubmed: 31116675
Eur Heart J. 2021 Dec 21;42(48):4964-4977
pubmed: 34529770
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Front Pharmacol. 2020 Jan 30;10:1671
pubmed: 32082164
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
Ann Oncol. 2017 Oct 01;28(10):2377-2385
pubmed: 28945858
J Am Coll Cardiol. 2020 Feb 18;75(6):620-628
pubmed: 32057377
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
N Engl J Med. 2021 Jun 3;384(22):2102-2114
pubmed: 34077643
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Front Immunol. 2021 Oct 18;12:754436
pubmed: 34733287
JACC CardioOncol. 2021 Mar;3(1):137-139
pubmed: 33796869
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
J Immunother Cancer. 2018 Nov 23;6(1):128
pubmed: 30470252
J Immunol. 2011 Feb 1;186(3):1338-42
pubmed: 21199897
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
BioDrugs. 2016 Dec;30(6):571-584
pubmed: 27848165
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Clin Oncol. 2020 May 20;38(15):1655-1663
pubmed: 32053428
J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76
pubmed: 32746624
Nat Commun. 2021 Feb 1;12(1):729
pubmed: 33526794
Eur J Cancer. 2021 May;149:153-164
pubmed: 33865201
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973
Int Immunol. 2016 Aug;28(8):411-9
pubmed: 27048318
Signal Transduct Target Ther. 2022 Apr 6;7(1):99
pubmed: 35383142
J Exp Med. 1991 Mar 1;173(3):721-30
pubmed: 1847722
JAMA Oncol. 2020 Apr 1;6(4):519-527
pubmed: 31895407
JAMA Oncol. 2018 Feb 01;4(2):173-182
pubmed: 28973656
Front Immunol. 2021 Jan 08;11:615317
pubmed: 33488626
J Immunol. 2000 May 15;164(10):5319-27
pubmed: 10799894
Radiology. 2021 Dec;301(3):602-609
pubmed: 34581628
PLoS One. 2020 Sep 2;15(9):e0238536
pubmed: 32877435
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Onco Targets Ther. 2018 Feb 23;11:955-965
pubmed: 29503570
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791